Ceritinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ceritinib: From ALK+ Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Ceritinib (Zykadia®) is a second-generation, oral anaplastic lymphoma kinase (ALK) inhibitor originally developed and approved for the treatment of ALK-rearranged non-small cell lung cancer (NSCLC). The TxGNN model predicts it may be effective for Gingival Fibromatosis with a prediction score of 99.86%, yet no clinical trials and no supporting publications exist for this indication. The mechanistic link between ALK inhibition and gingival fibromatosis is not established; this prediction likely reflects a knowledge graph generalization artifact rather than a true biological relationship.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive non-small cell lung cancer (NSCLC) |
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| EU Market Status | Not found in dataset (0 authorizations recorded) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Ceritinib is a potent and selective second-generation ALK tyrosine kinase inhibitor — approximately 20-fold more potent than the first-generation inhibitor crizotinib. It competitively blocks the ATP-binding site of the ALK kinase domain, suppressing downstream proliferative and survival signaling in tumors driven by ALK fusion genes (most commonly EML4-ALK in NSCLC). Ceritinib also inhibits IGF-1R and FAK at clinically relevant concentrations.
Gingival fibromatosis is a rare benign condition characterized by progressive fibrous overgrowth of gingival connective tissue. Its primary pathophysiological drivers are TGF-β/SMAD pathway activation and excessive gingival fibroblast proliferation — mechanisms entirely distinct from ALK-driven oncogenesis. ALK has no established expression, mutation, or functional role in gingival fibromatosis in the published literature.
The high TxGNN prediction score (99.86%) for this pairing is most likely attributable to a knowledge graph topology effect: “fibromatosis” disease nodes cluster near other fibrotic or proliferative conditions (such as ALK-positive inflammatory myofibroblastic tumors) within the graph, creating proximity-based score inflation that does not reflect biological plausibility. Without any mechanistic evidence or supporting literature, this prediction does not support further development.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorizations are recorded for Ceritinib in the current dataset.
Dataset note: Ceritinib (Zykadia®, Novartis) received EMA marketing authorization in May 2015 for ALK-positive NSCLC. The absence of records here may indicate a data gap or a subsequent regulatory change. Please verify current EU authorization status directly via the EMA product page.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — Second-generation ALK tyrosine kinase inhibitor (small molecule, oral) |
| Myelosuppression Risk | Low (ALK inhibitors have minimal direct myelotoxicity; hematological toxicity is not a primary concern) |
| Emetogenicity Classification | Low to moderate (GI adverse effects including nausea, diarrhea, and vomiting are common at standard doses) |
| Monitoring Items | Liver function (ALT/AST/bilirubin), serum amylase and lipase (pancreatitis risk), fasting blood glucose, ECG (QTc prolongation), CBC |
| Handling Protection | Standard oral cytotoxic handling precautions apply per institutional policy |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No mechanistic basis links ceritinib’s ALK inhibition to gingival fibromatosis — the condition is driven by TGF-β/SMAD fibroblast hyperactivation, not ALK signaling — and the evidence level is L5 (model prediction only, zero clinical or pre-clinical studies). The high TxGNN score is assessed as a knowledge graph generalization artifact.
To proceed, the following would be needed:
- Evidence of ALK expression or constitutive activation in gingival fibroblasts or gingival fibromatosis biopsy tissue
- Mechanistic studies demonstrating ALK pathway crosstalk with TGF-β/SMAD-driven fibrosis
- Resolution of the MOA data gap (DrugBank query recommended)
- Complete safety profile from the EMA SmPC, including key warnings and contraindications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.